MediciNova Inc
Fechado
SetorSaúde
1.78 4.71
Visão Geral
Variação de preço das ações
24h
Mín
1.78
Máximo
1.8
Rendimento | -2.3B -2.3B |
|---|---|
Vendas | 271K 458K |
EPS | -0.05 |
Margem de lucro | -504,786.678 |
Funcionários | 6 |
EBITDA | 5.1K -2.5M |
Próximos Ganhos | 10 de nov. de 2026 |
|---|
Capitalização de Mercado | 15M 80M |
|---|---|
Abertura anterior | -2.93 |
Fecho anterior | 1.78 |
Sentimento de Notícias
By Acuity
52%
48%
252 / 339 Ranking em Healthcare
MediciNova Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
MediciNova Inc Previsão
Sentimento
By Acuity
252 / 339 Ranking em Saúde
Sentimento de Notícias
Evidência de Tendência de Baixa
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Acima da média
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre MediciNova Inc
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.